Last updated: February 15, 2026
Drug Overview
NDC 66220-0637 corresponds to Tucidinon (Etoposide Capsules), indicated primarily for the treatment of various malignancies such as lung cancer, lymphomas, and testicular cancer. It is a generic formulation of the chemotherapeutic agent Etoposide.
Market Size and Dynamics
The global oncology drug market surpasses $250 billion annually and is projected to grow at a compound annual growth rate (CAGR) of approximately 7% through 2028[^1]. Etoposide, as a standard chemotherapy medication, maintains a significant portion of this market, especially in oncology drug regimens for lung, testicular, and lymphoma treatments.
Market Drivers
- Increasing global cancer incidence rates, particularly in developing regions[^2].
- Expansion of combination chemotherapy protocols incorporating Etoposide.
- Growing approval of generic versions reducing costs and expanding access.
- Increased adoption in developing healthcare systems due to price competitiveness.
Key Manufacturers and Market Share
Major producers include Teva Pharmaceutical Industries, Sandoz (Novartis), and Mylan (now part of Viatris). These players dominate the generics segment, with market shares roughly split evenly among leading companies[^3].
Pricing Landscape
- Brand name: Brand formulations (e.g., Vumon) can retail at prices exceeding $1,000 per vial in the U.S.
- Generic: Prices vary significantly by region and supplier. In the United States, average vial prices range from $50 to $200. Internationally, prices are lower due to regulatory and market conditions.
| Region |
Typical Cost per Dose |
Notes |
| United States |
$50 – $200 |
Due to insurance negotiations and pharmacy discounts. |
| European Union |
$30 – $150 |
Depending on country and procurement channels. |
| Asia-Pacific |
$10 – $70 |
Lower prices dominate due to local manufacturing. |
Price Drivers
- Regulatory approval status and patent expiry influence competition.
- Manufacturing costs, including those associated with Good Manufacturing Practices (GMP).
- Local procurement policies and reimbursement landscapes.
- Supply chain stability, which affects availability and pricing.
Regulatory and Policy Considerations
- The expiration of patents for the primary formulation has allowed multiple generics to enter the market, decreasing prices.
- In the U.S., the FDA approved the first generic version in 2014. Other regions follow similar timelines, typically within 2-4 years of patent expiry.
- Price caps or controls in some European countries limit maximum allowable prices for chemotherapeutics, impacting profit margins.
Future Price Projections
- Short-term (1–2 years): Prices are expected to stabilize, maintaining current generic price ranges due to market saturation.
- Medium-term (3–5 years): Prices could decline an additional 10–20% if generic manufacturers increase production and market penetration.
- Long-term (5+ years): Advancements in targeted therapies and immunotherapies may supersede traditional chemotherapies, potentially reducing demand and pricing for Etoposide formulations.
Market Opportunities and Risks
- Opportunities include expanding into emerging markets and developing combination drug regimens.
- Risks encompass reduced demand due to newer treatment modalities, pricing pressures from payers, and potential supply chain disruptions.
Summary
NDC 66220-0637, as a generic Etoposide formulation, operates within a mature but competitive chemotherapy market. Its pricing remains relatively stable, with moderate downward pressure projected as competition intensifies and newer therapies emerge. Market growth tied to global cancer incidence will sustain demand, but evolving treatment standards could impact long-term valuation.
Key Takeaways
- The global oncology market's growth supports sustained demand for Etoposide generics.
- Pricing in the U.S. ranges from $50 to $200 per vial; international prices tend to be lower.
- Patent expiries and regulatory approvals have increased generic competition, exerting downward pressure on prices.
- Long-term prospects may diminish as targeted and immunotherapeutic options expand.
- Regions with expanding healthcare access and less regulatory price controls represent growth opportunities.
FAQs
1. What is the primary use of NDC 66220-0637?
Etoposide capsules are used in chemotherapy for cancers such as lung, lymphomas, and testicular cancers.
2. How do current prices for this drug compare globally?
US prices range from $50 to $200 per vial, while international prices are generally lower, often below $70 per dose.
3. Will prices decline further?
Yes, prices are expected to decline gradually due to increased generic competition and market saturation.
4. How does patent expiry influence market dynamics?
Patent expiry leads to multiple generics entering the market, decreasing prices and increasing access.
5. Are there emerging therapies that threaten the market for Etoposide?
Yes, targeted therapies and immunotherapies are increasingly replacing traditional chemotherapies in some indications, which could reduce demand.
References
[1] IQVIA, "Global Oncology Market Report," 2022.
[2] World Health Organization, "Cancer Fact Sheet," 2022.
[3] EvaluatePharma, "Generic Drug Market Share Analysis," 2023.
